|Dr. James Neil Phillips||Chief Exec. Officer & Director||670.5k||N/A||1962|
|Mr. Nicholas John Robbins-Cherry||CFO, Company Sec. & Director||317.78k||N/A||1969|
|Dr. Craig Cook||Chief Operating Officer||N/A||N/A||1967|
|Dr. Dan Palmer Ph.D., MBA||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Rob Rainey FCA MBA MA||Head of Corp. Devel.||N/A||N/A||N/A|
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Midatech Pharma Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.